Isomorphic Labs and Merck partner to design new cancer drug
According to Isomorphic Labs and a post by Demis Hassabis cited by X, Isomorphic Labs entered a strategic research collaboration with Merck to design a new cancer drug using frontier AI and Merck’s development expertise.
SourceAnalysis
On November 20, 2026, Demis Hassabis announced a strategic research collaboration between Isomorphic Labs and MSD, known as Merck, focused on designing a new cancer drug through AI-powered methods.
Details of the Isomorphic Labs and MSD Partnership
The agreement integrates Isomorphic Labs world-leading frontier AI capabilities with MSDs deep expertise in discovery, development and manufacturing, according to the announcement from Isomorphic Labs.
Practical Effects on Pharmaceutical Workflows
This development illustrates how AI tools accelerate drug design processes, enabling professionals in biotechnology to identify candidates faster and reshape traditional research timelines in the pharma sector.
Broader Implications for the AI Ecosystem
The collaboration highlights ongoing advances in applying AI to scientific discovery, with direct effects on industry practices that combine computational models and experimental validation for more efficient therapeutic development.
Demis Hassabis
@demishassabisNobel Laureate and DeepMind CEO pursuing AGI development while transforming drug discovery at Isomorphic Labs.